Answers are grounded in this paper and cite their sources.
Just a half century has passed since the discovery of Epstein-Barr virus (EBV). Chronic active EBV infection (CAEBV) is a prototype of EBV-associated T- or NK-cell lymphoproliferative diseases (EBV+T/NK-cell LPDs). The latest guideline for diagnosing CAEBV was proposed by Okano et al (2005). Definitive diagnosis requires evidence of EBV-infected T/NKcell proliferation (practically, evidence of high EBV load and EBV infection to T/NK cells) in the patient. However, the necessary tests are not covered by National Health Insurance, so a more invasive approach (a biopsy of the involved tissue) is needed. Because CAEBV patients possibly experience lethal hypercytokinemia, they should undergo immunochemotherapy followed by multi-drug chemotherapy, and need a preparation of allogeneic hematopoietic stem celltransplantation (HSCT). In cases of insufficient control of the symptoms and a progression of the disease, an allogeneic HSCT might be urgently required. Reduced-intensity conditioning is better than myeloablative conditioning, the overall survival rate is equally > 90% after bone marrow transplantation and cord blood transplantation, and the outcome is not inferior in young adults (<40 years old) compared to that in children.
No takes yet. Share an insight, caveat, or question.
Sawada et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: